Mrs Sabrina S Mayton, OT/L | |
2830 Lew Jones Rd, Alberta, VA 23821-2540 | |
(434) 480-2281 | |
Not Available |
Full Name | Mrs Sabrina S Mayton |
---|---|
Gender | Female |
Speciality | Occupational Therapist - Environmental Modification |
Location | 2830 Lew Jones Rd, Alberta, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255195160 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225XE0001X | Occupational Therapist - Environmental Modification | 0119004531 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Sabrina S Mayton, OT/L 2830 Lew Jones Rd, Alberta, VA 23821-2540 Ph: (434) 480-2281 | Mrs Sabrina S Mayton, OT/L 2830 Lew Jones Rd, Alberta, VA 23821-2540 Ph: (434) 480-2281 |
News Archive
Physicians and their patients alike know that physical activity is an important component of a healthy lifestyle, but what is less clear is what kind of a role doctors should have in increasing their patients' activity levels.
The Center for American Progress proposed a "fail-safe" mechanism designed to ensure that a health care overhaul wouldn't add to the federal deficit today. The plan, part of a financing proposal for health care legislation that was released at a breakfast with reporters, is aimed at addressing concerns that a revamping might not produce expected cost savings over the long run, leading to a big increase in the budget gap.
Gentium S.p.A. today reported financial results for the first half of 2010 and for the quarter ended June 30, 2010. The Company reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP). The Company's financial statements are prepared using the Euro as its functional currency.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
Erasing memories that link environmental cues to drug use could represent a potential new treatment for drug addiction and prevent relapse.
› Verified 2 days ago